{
    "clinical_study": {
        "@rank": "143063", 
        "arm_group": [
            {
                "arm_group_label": "LEE011 + BKM120 + fulvestrant", 
                "arm_group_type": "Experimental", 
                "description": "LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating) BKM120 - daily (dose escalating) fulvestrant - i.m. - 500 mg given on day 1 and day 15 of Cycle 1, then on Day 1 of each subsequent cycle."
            }, 
            {
                "arm_group_label": "LEE011 + BYL719 + fulvestrant", 
                "arm_group_type": "Experimental", 
                "description": "LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating) BYL719 - daily (dose escalating) fulvestrant - i.m. - 500 mg given on day 1 and day 15 of Cycle 1, then on Day 1 of each subsequent cycle."
            }, 
            {
                "arm_group_label": "LEE011 + fulvestrant", 
                "arm_group_type": "Experimental", 
                "description": "LEE011 - 28 day cycles (21 days followed by a 7 day break) fulvestrant - 500 mg i.m. given on Day 1 and Day 15 of Cycle 1, then on Day 1 of each subsequent cycle."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to explore the clinical utility of the three investigational\n      agents in HR+, HER2- breast cancer. LEE011 (CDK4/6 inhibitor), BKM120 (PI3K-pan class\n      I-inhibitor) and BYL719 (PI3K-alpha specific class I inhibitor) in combination with\n      fulvestrant.\n\n      This is a multi-center, open-label Phase Ib/II study. The Phase Ib portion of the study is a\n      dose escalation to estimate the MTD and/or RP2D for three regimens: LEE011 with fulvestrant;\n      LEE011 and BKM120 with fulvestrant; LEE011and BYL719 with fulvestrant.\n\n      The Phase II portion of the study will be a randomized study to assess the anti-tumor\n      activity as well as safety and tolerability of  LEE011 with fulvestrant to LEE011 and BKM120\n      with fulvestrant,  and LEE011 and BYL719 with fulvestrant in patients with  ER+/HER2-\n      locally advanced or metastatic breast cancer.\n\n      Approximately 216 adult women with ER+/HER2- locally advanced or metastatic breast cancer\n      will be enrolled."
        }, 
        "brief_title": "Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Postmenopausal, Hormone receptor positive (HR+), HER2 negative breast cancer\n\n          -  Unlimited number of lines of endocrine therapy and up to two lines of cytotoxic\n             chemotherapy in the metastatic setting  (Phase Ib)\n\n          -  Unlimited number of lines of endocrine therapy and one line of cytotoxic chemotherapy\n             in the metastatic setting (Phase II)\n\n        Exclusion Criteria:\n\n          -  HER2-overexpression in the patient's tumor tissue\n\n          -  Inadequate bone marrow function or evidence of end-organ damage\n\n          -  Severe or uncontrolled medical issues\n\n          -  Diabetes mellitus\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "216", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02088684", 
            "org_study_id": "CLEE011X2108"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LEE011 + BKM120 + fulvestrant", 
                    "LEE011 + BYL719 + fulvestrant", 
                    "LEE011 + fulvestrant"
                ], 
                "description": "LEE011: supplied as capsules of dosage strength of 50 mg or 200 mg. The capsules or will be differentiated through different sizes", 
                "intervention_name": "LEE011", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LEE011 + BYL719 + fulvestrant", 
                "description": "BYL719: supplied as tablets of dosage strength of 10 mg, 50 mg or 200 mg. Tablets will be differentiated through different sizes and/or colors.", 
                "intervention_name": "BYL719", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "LEE011 + BKM120 + fulvestrant", 
                    "LEE011 + BYL719 + fulvestrant", 
                    "LEE011 + fulvestrant"
                ], 
                "description": "Fulvestrant will be supplied according to local practice and regulation. Fulvestrant is a commercially available product, comes in 500 mg dose and is an injection for intramuscular (i.m.) administration.", 
                "intervention_name": "fulvestrant", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LEE011 + BKM120 + fulvestrant", 
                "description": "BKM120: supplied as 10 mg or 50 mg capsules. The capsules will be differentiated through different sizes.", 
                "intervention_name": "BKM120", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fulvestrant", 
                "Estradiol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Hormone receptor positive, HER2 negative", 
        "lastchanged_date": "March 13, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Phase Ib/II Study of LEE011 in Combination With Fulvestrant and BYL719 or BKM120 in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Recurrent or Advanced Metastatic Breast Cancer", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Singapore: Health Sciences Authority", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Italy: National Institute of Health", 
                "South Korea: Korea Food and Drug Administration (KFDA)", 
                "Taiwan: Center for Drug Evaluation", 
                "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Dose limiting toxicities", 
                "measure": "Incidence of Dose limiting toxicities (DLTs) - Phase lb only", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Progression Free Survival per RECIST v 1.1 by local investigator assessment", 
                "measure": "Progression free survival (PFS) - Phase ll only", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02088684"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse Events (AEs), serious AEs (SAEs), changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, reductions and dose intensity", 
                "measure": "Safety and Tolerability of the combinations of LEE011 with fulvestrant, LEE011 + BKM120 with fulvestrant and LEE011 + BYL719 with fulvestrant", 
                "safety_issue": "Yes", 
                "time_frame": "36 months"
            }, 
            {
                "description": "To characterize the PK profiles of LEE011, BKM120, BYL719, and fulvestrant when used in combination as well as to evaluate any other clinically significant metabolites that may be identified. PK parameters for LEE011, BKM120 and BYL719, including but not limited to Cmax, Cmin, Tmax, AUCtau, accumulation ratio (Racc),and Ctrough values for fulvestrant.", 
                "measure": "Plasma concentration-time profiles of LEE011, BKM120, BYL719 and fulvestrant.", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "ORR is defined as the proportion of patients with a best overall response of complete response or partial response.", 
                "measure": "Overall Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Duration of Response is calculated as the time from the date of first documented response (complete response (CR) or partial response (PR)) to the first documented date of progression or death due to underlying cancer.", 
                "measure": "Duration of Response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "PFS is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause.", 
                "measure": "Progression Free Survival (PFS) (pahse l only)", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "OS is defined as the time from date of randomization/start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last known date patient alive.", 
                "measure": "Overall Survival (OS) - Phase II only", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}